Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 8, 2012

Moffitt Cancer Center, Sanford-Burnham, and Florida Hospital Forge Pact

  • Moffitt Cancer Center, Sanford-Burnham Medical Research Institute, and Florida Hospital are collaborating to create a Personalized Medicine Partnership of Florida (PMP Florida). The aim is to accelerate discovery and development of new treatments in the areas of cancer and metabolic diseases.

    The partnership will leverage Florida Hospital’s large patient population and clinical research expertise, Sanford-Burnham’s research expertise and technology platforms, and Moffitt’s biospecimen bank, data warehouse, and personalized medicine capabilities. One of the objectives of the partnership is to attract industry clients to utilize this resource.

    PMP Florida will look to create alliances among Florida-based centers of excellence in medical research and clinical care. Together, the organizations will develop and utilize new molecular and genomic technologies to discover, translate, and personalize interventions for preventing and treating debilitating diseases.

    It will try to mimick Moffitt’s Total Cancer Care™ to develop similar research and clinical protocols in other disease areas including metabolic diseases. Total Cancer Care is a treatment path that begins by mapping the more than 30,000 genes that make up a tumor to find its own unique genetic fingerprint.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »